Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
Author(s)
Type
Journal Article
Abstract
In non‐small cell lung cancer, sensitizing mutations in epidermal growth factor receptor (EGFR) or cMET amplification serve as good biomarkers for targeted therapies against EGFR or cMET, respectively. Here we aimed to determine how this different genetic background would affect the interaction between the EGFR‐inhibitor erlotinib and the cMET‐inhibitor crizotinib. To unravel the mechanism of synergy we investigated the effect of the drugs on various parameters, including cell cycle arrest, migration, protein phosphorylation, kinase activity, the expression of drug efflux pumps, intracellular drug concentrations, and live‐cell microscopy. We observed additive effects in EBC‐1, H1975, and HCC827, and a strong synergism in the HCC827GR5 cell line. This cell line is a clone of the HCC827 cells that harbor an EGFR exon 19 deletion and has been made resistant to the EGFR‐inhibitor gefitinib, resulting in cMET amplification. Remarkably, the intracellular concentration of crizotinib was significantly higher in HCC827GR5 compared to the parental HCC827 cell line. Furthermore, live‐cell microscopy with a pH‐sensitive probe showed a differential reaction of the pH in the cytoplasm and the lysosomes after drug treatment in the HCC827GR5 in comparison with the HCC827 cells. This change in pH could influence the process of lysosomal sequestration of drugs. These results led us to the conclusion that lysosomal sequestration is involved in the strong synergistic reaction of the HCC827GR5 cell line to crizotinib–erlotinib combination. This finding warrants future clinical studies to evaluate whether genetic background and lysosomal sequestration could guide tailored therapeutic interventions.
Date Issued
2020-01-20
Date Acceptance
2019-12-23
Citation
Journal of Cellular Physiology, 2020, 235 (11), pp.8085-8097
ISSN
0021-9541
Publisher
Wiley
Start Page
8085
End Page
8097
Journal / Book Title
Journal of Cellular Physiology
Volume
235
Issue
11
Copyright Statement
© 2020 The Authors. Journal of Cellular Physiology published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This is an open access article under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000508127400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Cell Biology
Physiology
cMET
crizotinib
EGFR
erlotinib
lysosomes
tyrosine kinase inhibitors
GROWTH-FACTOR RECEPTOR
LUNG-CANCER
PHYSICOCHEMICAL PROPERTIES
KINASE INHIBITORS
MET
AUTOPHAGY
AMPLIFICATION
SEQUESTRATION
OSIMERTINIB
Publication Status
Published
Date Publish Online
2020-01-20